Asked About ‘TACO' and Tariffs, Trump Lashes Out at Reporter
President Trump, it would seem, is not one for a 'TACO.' The taco in question is not a dish made with tortillas, but rather a reference to how markets are responding to his tariff policies.
The TACO trade, short for Trump Always Chickens Out, is a tongue-in-cheek term coined by the Financial Times columnist Robert Armstrong. It has been adopted by some analysts and commentators to describe the potentially lucrative pattern in which markets tumble after Mr. Trump makes tariff threats, only to rebound sharply when he relents and allows countries more time to negotiate deals.
The president has spent years cultivating a reputation for political muscle. So when he was asked by a reporter in the Oval Office on Wednesday whether the term might be a valid description of his approach to tariffs, Mr. Trump reacted with ire.
'I chicken out? I've never heard that,' he said. 'Don't ever say what you said,' he told the reporter. 'That's a nasty question. To me, that's the nastiest question.'
But gyrations driven by the president's on-again, off-again tariffs are by now taken for granted on Wall Street. Stock markets jumped on Tuesday, for example, after Mr. Trump delayed a proposed 50 percent tariff on the European Union that he had threatened only a few days earlier.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Do Merit Medical Systems' (NASDAQ:MMSI) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad. Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Merit Medical Systems (NASDAQ:MMSI). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. If a company can keep growing earnings per share (EPS) long enough, its share price should eventually follow. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. It certainly is nice to see that Merit Medical Systems has managed to grow EPS by 34% per year over three years. As a general rule, we'd say that if a company can keep up that sort of growth, shareholders will be beaming. Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. Merit Medical Systems maintained stable EBIT margins over the last year, all while growing revenue 8.2% to US$1.4b. That's a real positive. In the chart below, you can see how the company has grown earnings and revenue, over time. Click on the chart to see the exact numbers. View our latest analysis for Merit Medical Systems The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for Merit Medical Systems' future EPS 100% free. We would not expect to see insiders owning a large percentage of a US$5.6b company like Merit Medical Systems. But we do take comfort from the fact that they are investors in the company. Notably, they have an enviable stake in the company, worth US$132m. Holders should find this level of insider commitment quite encouraging, since it would ensure that the leaders of the company would also experience their success, or failure, with the stock. If you believe that share price follows earnings per share you should definitely be delving further into Merit Medical Systems' strong EPS growth. With EPS growth rates like that, it's hardly surprising to see company higher-ups place confidence in the company through continuing to hold a significant investment. On the balance of its merits, solid EPS growth and company insiders who are aligned with the shareholders would indicate a business that is worthy of further research. However, before you get too excited we've discovered 1 warning sign for Merit Medical Systems that you should be aware of. There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a tailored list of companies which have demonstrated growth backed by significant insider holdings. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
34 minutes ago
- Wall Street Journal
What's Good for Politicians Is Good for General Motors
General Motors CEO Mary Barra earned $29.5 million last year, and it's hard to argue that she isn't earning her keep. The automaker sold more cars in the U.S. than any other company last year, and its profits have doubled in her 11 years as CEO. Credit her ability to please her most important customers—politicians. Their command is her wish. While doubling down on manufacturing profitable gas guzzlers, Ms. Barra promoted electric vehicles to ingratiate herself to Democrats who want to eliminate the products that churn out profits for her company. She again proved her flexible principles last week by praising President Trump's auto tariffs, which the company estimates will dent its profits by $5 billion this year. 'I think tariffs is one tool that the administration can use to level the playing field,' she said. What she omitted is that the playing field has been tilted in GM's favor for decades by a 25% tariff on pickup trucks, which gives domestic automakers an effective monopoly. Also: Mr. Trump's new 25% tariffs on all cars and parts not made in the U.S. will hurt GM, but they will wallop its foreign competitors even more. In 2018 Ms. Barra got a crash course in politicking when she announced a corporate restructuring that involved closing four U.S. plants that produced low-selling sedans. Her goal was to make GM leaner and more profitable. In this she succeeded, but she blundered by not throwing a bone to Mr. Trump, who thinks CEOs answer to him.
Yahoo
35 minutes ago
- Yahoo
The mechanisms of accountability have been dismantled: Baker on Trump's fringe appointees
President Trump continues to appoint controversial figures to federal office, now with a former podcast host with a history of inflammatory comments being tapped for a top ethics position. Chief White House Correspondent of the New York Times Peter Baker and NBC News White House Correspondent Vaughn Hillyard join The Weekend to discuss.
